Sean O'Connor is a Principal at Longwood Fund who previously served as a Principal investor at the T1D Fund, where he led investments in companies like SAB Biotherapeutics and vTv Therapeutics, giving him distinctive experience translating disease-focused philanthropic capital into venture-backed biotech platforms. His career path from academic research in microRNA and adipocyte metabolism at The Rockefeller University through top-tier healthcare consulting at Boston Consulting Group to specialized autoimmune and metabolic disease investing provides him an end-to-end view from fundamental biology through strategy, financing, and scale-up that is relatively uncommon for a Principal-level investor.